Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Attachment in children

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Attachment in children. Displaying page 1 of 1.
    EudraCT Number: 2014-005352-25 Sponsor Protocol Number: ML11283 Start Date*: 2015-08-07
    Sponsor Name:KU Leuven
    Full Title: The effect of oxytocin on the training of attachment-related interpretation bias
    Medical condition: General population children (ages 8 - 13 years old)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000156-11 Sponsor Protocol Number: S65914 Start Date*: 2022-02-25
    Sponsor Name:KU Leuven
    Full Title: Oxytocin and the development of attachment: Looking beyond the expected?
    Medical condition: General healthy population children (ages 8 - 13 years old).
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012520-84 Sponsor Protocol Number: 0881A1-3338 Start Date*: 2009-08-19
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate...
    Medical condition: Extended oligoarticular juvenile idiopathic arthritis (JIA) Enthesitis-related arthritis (ERA) Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003246 Arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) BE (Completed) CZ (Completed) FR (Completed) SI (Completed) ES (Completed) SE (Prematurely Ended) SK (Completed) LT (Completed) NL (Completed) LV (Completed) GR (Completed) DK (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-003941-42 Sponsor Protocol Number: B4Z-SO-LY15 Start Date*: 2005-02-11
    Sponsor Name:Eli Lilly Sweden AB
    Full Title: A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and ...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD) is a common psychiatric disorder that has its onset in childhood, and that is estimated to occur in 3% to 6% of school-age children. ADHD is characte...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005101-51 Sponsor Protocol Number: RIVM-V/330564/01 Start Date*: 2013-02-05
    Sponsor Name:National Institute of Health and the Environment (Dutch acronym: RIVM)
    Full Title: Tick Test & Prophylaxis Proof
    Medical condition: Lyme disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10025169 Lyme disease PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000453-44 Sponsor Protocol Number: NL42746.058.12 Start Date*: 2013-06-19
    Sponsor Name:
    Full Title: The full scope of oxytocinergic influences on the parental brain: Maternal defensiveness and grandparent-child interactions
    Medical condition: There are no medical conditions or diseases under investigation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10033329 Oxytocin PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000454-22 Sponsor Protocol Number: NL43068.058.13 Start Date*: 2013-08-21
    Sponsor Name:
    Full Title: (Grand)parenting, oxytocin, and the oxytocin receptor gene: an fMRI and observational study
    Medical condition: There are no medical conditions or diseases under investigation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10033329 Oxytocin PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014368-20 Sponsor Protocol Number: CNTO1275PSO3006 Start Date*: 2011-01-06
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-t...
    Medical condition: Moderate to Severe Plaque-type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) PT (Completed) FR (Completed) BE (Completed) HU (Completed) GB (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005701-32 Sponsor Protocol Number: B4Z-IT-LYDS Start Date*: 2006-03-07
    Sponsor Name:ELI LILLY
    Full Title: An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without comorbid conditions
    Medical condition: Child or adolescent patients with Attention-Deficit/ Hyperactivity Disorder ADHD
    Disease: Version SOC Term Classification Code Term Level
    6.1 10003736 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000191-24 Sponsor Protocol Number: B4Z-UT-LYEL Start Date*: 2008-05-09
    Sponsor Name:Eli Lilly Nederland
    Full Title: An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents with Attentioin-Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003736 Attention deficit/hyperactivity disorder LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004088-31 Sponsor Protocol Number: B4Z-XM-LYDM Start Date*: 2005-04-19
    Sponsor Name:Lilly S.A.
    Full Title: A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 weeks in Newly Diagnosed Children and Adolescents Outpatients with Attention-Deficit/Hyp...
    Medical condition: Attention-Deficit/Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-005425-11 Sponsor Protocol Number: 3144A2-3003/B1891003 Start Date*: 2009-01-14
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
    Full Title: A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer
    Medical condition: Locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) SI (Completed) BE (Completed) DE (Completed) ES (Completed) CZ (Completed) IT (Prematurely Ended) GR (Completed) FR (Completed) AT (Completed) GB (Completed) BG (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000769-35 Sponsor Protocol Number: S61358 Start Date*: 2018-09-27
    Sponsor Name:University Hospital, KU Leuven
    Full Title: In search for an innovative neural marker and intervention for socio-communicative difficulties in children with and without autism spectrum disorders
    Medical condition: Autism Spectrum Disorders
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10003808 Autistic disorder LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015953-18 Sponsor Protocol Number: DORIPED3002 Start Date*: 2010-05-28
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infec...
    Medical condition: Complicated Urinary Tract Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10046571 Urinary tract infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) CZ (Completed) PL (Temporarily Halted) LV (Prematurely Ended) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001767-11 Sponsor Protocol Number: B4Z-EW-LYFJ Start Date*: 2008-08-19
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and A...
    Medical condition: Attention Deficit/Hyperactivity Disorder/ADHD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020380-20 Sponsor Protocol Number: R331333-PAI2005/KF5503-59 Start Date*: 2012-03-09
    Sponsor Name:Janssen Research & Development, L.L.C.
    Full Title: Open-Label Evaluation of the Pharmacokinetic Profile and Safety of Tapentadol Oral Solution for the Treatment of Postsurgical Pain in Children and Adolescents Aged From 6 to Less Than 18 Years
    Medical condition: Pain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10033371 Pain PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-000371-42 Sponsor Protocol Number: 3066K1-139-US Start Date*: 2007-09-20
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaeuticals Inc.
    Full Title: A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors
    Medical condition: Relapsed/refractory neuroblastoma,high-grade glioma, and rhabdomyosarcoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018338 Glioma LLT
    9.1 10029260 Neuroblastoma LLT
    9.1 10039022 Rhabdomyosarcoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003377-34 Sponsor Protocol Number: 54767414ALL2005 Start Date*: 2018-07-31
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age With Relapsed/Refractory Precursor B-cell o...
    Medical condition: Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    20.0 100000004864 10066110 T-cell lymphoblastic leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) FR (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001552-19 Sponsor Protocol Number: TOPMATEPY4067 Start Date*: 2014-12-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared with Levetiracetam as Monotherapy in Pediatric Subjects ...
    Medical condition: New-onset or recent-onset epilepsy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed) HU (Completed) BE (Completed) DE (Completed) GB (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004837-54 Sponsor Protocol Number: RABGRD3003 Start Date*: 2009-03-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Parallel-Group Study to Evaluate Short-Term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formul...
    Medical condition: Endoscopically proven gastroesophageal reflux disease (GERD) in a paediatric population of 1 to 11 year old subjects.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018203 GERD LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) FR (Completed) NL (Ongoing) IT (Completed) BG (Not Authorised)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 23 16:48:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA